BioMarin Pharmaceutical | BMRN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
Bayer EUR 4.02B 53M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 364.27M 12.54M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Moderna USD 282M 66M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 140M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09